Search Product
Structure Search
Search
Online Support
-
Customer service
Advantage Products
Location: Industrial Info
GSK launches new diabetes drug Tanzeum in United States
2014-08-05
来源：转载自第三方
GlaxoSmithKline (GSK) has announced the launch of a new drug, Tanzeum (albiglutide) in United States, which is a weekly subcutaneous injection drugs, assisted diet and exercise to improve type 2 blood glucose control in adults with diabetes mellitus.
Tanzeum was approved by the FDA in April 2014, and the drug was approved on a comprehensive Phase III Harmony project, which included eight trials involving more than 5,000 patients, of whom more than 2,000 patients received Tanzeum treatment. The Harmony project evaluated the efficacy and safety of albiglutide versus conventional type 2 diabetes drugs (including insulin, metformin, glimepiride, pioglitazone) in different stages of type 2 diabetes mellitus.
Albiglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, a biological product developed for the treatment of type 2 diabetes, subcutaneously injection once a week. The drug is GLP-1 drug like Victoza of Novo Nordisk's, Byetta and Bydureon of Bristol-Myers Squibb (BMS) and AstraZeneca Amylin units. The Albiglutide was originally developed by the Human Genomics Corporation (HGS). GLP-1 is an important urinary insulin hormone that helps restore normal blood sugar levels.
In the EU, albiglutide was approved by the European Medicines Agency (EMA) in March 2014 as the brand name Epenzan.
TAG: Chemical Reagents, Biomedicine
如果涉及转载授权，请联系我们。
